Mantle Cell Lymphoma

Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.

Moffitt Cancer Center investigators believe allo-HCT may actually be “curative” for patients with a certain type of lymphoma.

At time of analysis, 14 of the 22 complete responses were ongoing.

Preclinical models predict that ibrutinib and venetoclax would have a synergistic effect in dual inhibition for mantle cell lymphoma.

The most frequently reported grade 3 to 4 adverse events included neutropenia, infection, and cutaneous toxicity. Three treatment-related deaths (2 from sepsis and 1 from embolic stroke) were noted.

The median time to response (TRR) was 1.9 months. The median duration of response (DoR) was not reached, though the 12-month DoR rate was 72% (95% CI, 62-80%).

Patients who did not reach a first complete remission were twice as likely to fail rituximab maintenance therapy; patients who received autologous stem cell transplant had a decreased failure risk of 69%.

The FDA based its approval on evidence from the single-arm, LY-004 clinical study, for which researchers enrolled 124 patients with MCL to receive acalabrutinib 100 mg twice daily.